Irinotecan Fair-Med

Irinotecan, the active ingredient in Irinotecan Fair-Med, is a topoisomerase I inhibitor presented as a sterile injectable powder for intravenous use. It treats colorectal cancer, including metastatic disease, in adult patients. GNH USA supplies Irinotecan Fair-Med as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Fair-Med is employed in the management of colorectal cancer and related disease stages, acting on tumor cells that rely on topoisomerase I activity. - Colorectal cancer: used in combination regimens to shrink primary tumors and improve survival. - Metastatic colorectal cancer: administered to control disease spread and extend patient lifespan. - Advanced colorectal cancer: incorporated into second‑line therapy when first‑line options have failed.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Diarrhea: often delayed, may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Anemia: decreased red blood cell production leading to low hemoglobin.

Serious or Rare Side Effects: - Febrile neutropenia: fever with severe neutropenia requiring urgent care. - Severe colitis: intense, bloody diarrhea that can be life‑threatening. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe electrolyte disturbances: hypokalemia or hyponatremia.

Prior to initiating Irinotecan Fair-Med, clinicians should evaluate several safety parameters. - Baseline blood counts: monitor for neutropenia and anemia throughout therapy. - Liver function: assess hepatic enzymes as impairment may increase drug exposure. - Biliary obstruction: avoid in patients with known blockage to reduce risk of severe diarrhea. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and toxicity. - Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may exacerbate constipation associated with irinotecan. - Warfarin: potential alteration of INR requiring closer coagulation monitoring. - Fluoropyrimidines (e.g., 5‑FU): additive gastrointestinal toxicity may necessitate dose adjustments.